-
Barouch D H, Nabel G J. 2005. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther, 16 (2): 149-156.
doi: 10.1089/hum.2005.16.149
-
Burton D R, Desrosiers R C, Doms R W, et al.2004. HIV vaccine design and the neutralizing antibody problem. Nat Immunol, 5 (3): 233-236.
doi: 10.1038/ni0304-233
-
Egan M A, Megati S. 2006. Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice. Vaccine, 24 (21): 4510-4523.
doi: 10.1016/j.vaccine.2005.08.024
-
Garber D A, Silvestri G, Feinberg M B. 2004. Prospects for an AIDS vaccine: three big questions, no easy answers.Lancet Infect Dis, 4 (7): 397-413.
doi: 10.1016/S1473-3099(04)01056-4
-
Girard M P, Osmanov S K, Kieny M P. 2006. A review of vaccine research and development: the human immu-nodeficiency virus (HIV).Vaccine, 24 (19): 4062-4081.
doi: 10.1016/j.vaccine.2006.02.031
-
Koff W C, Johnson P R, Watkins D I. 2006. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol, 7 (1): 19-23
doi: 10.1038/ni1296
-
Hinkula J. 2007. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity. Expert Rev Vaccines, 6 (2): 203-212
doi: 10.1586/14760584.6.2.203
-
Johnston M I, Fauci A S. 2007. An HIV vaccine--evolving concepts. N Engl J Med, 356 (20): 2073-2081.
doi: 10.1056/NEJMra066267
-
Kim D, Elizaga M, Duerr A. 2007. HIV vaccine efficacy trials: towards the future of HIV prevention. Infect Dis Clin North Am, 21 (1): 201-217.
doi: 10.1016/j.idc.2007.01.006
-
Koff W C, Johnson P R, Watkins D I, 2006. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol, 7 (1): 19-23.
doi: 10.1038/ni1296
-
Letvin N L. 2006. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol, 6 (12): 930-939.
doi: 10.1038/nri1959
-
Levy J A. 2006. HIV pathogenesis: knowledge gained after two decades of research. Adv Dent Res, 19 (1): 10-16.
doi: 10.1177/154407370601900104
-
McCoy, Tatsis N, Korioth-Schmltz B, et al. 2007. The effect of pre-existing immunity to antigens of adenovirus of the human serotype 5 on immune responses of nonhuman primates to vaccine regimens based on human or chim-panzee-derived adenovirus vectors. J Virol, 81 (12): 6594-6604.
doi: 10.1128/JVI.02497-06
-
Papp Z, Babiuk L A, Baca-Estrada M E. 1999. The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1.Vaccine, 17 (7-8): 933-943.
doi: 10.1016/S0264-410X(98)00279-5
-
Robinson H L. 2003. New hope for AIDS vaccine. Lancet, 361 (9371): 1799.
doi: 10.1016/S0140-6736(03)13455-1
-
Rodriguez-Chavez I R, Allen M, Hill E L, et al.2006. Current advances and challenges in HIV-1 vaccines.Curr HIV/AIDS Rep, 3 (1): 39-47.
doi: 10.1007/s11904-006-0007-0
-
Scanlan C N, Offer J, Zitzmann N, Dwek R A. 2007. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature, 446 (7139): 1038-1045.
doi: 10.1038/nature05818
-
Spearman P. 2003. HIV vaccine development: lessons from the past and promise for the future. Curr HIV Res, 1 (1): 101-120.
doi: 10.2174/1570162033352093
-
Thorner A R, Barouch D H. 2007. HIV-1 Vaccine Development: Progress and Prospects. Curr Infect Dis Rep, 9 (1): 71-75.
doi: 10.1007/s11908-007-0025-0
-
Vanniasinkam T, Ertl H C. 2005. Adenoviral gene delivery for HIV-1 vaccination. Curr Gene Ther, 5 (2): 203-212.
doi: 10.2174/1566523053544236
-
Veazey R S, Lackner A A. 2005. HIV swiftly guts the immune system. Nat Med, 11 (5): 469-470.
doi: 10.1038/nm0505-469